GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyowa Kirin Co Ltd (TSE:4151) » Definitions » Capex-to-Operating-Income

Kyowa Kirin Co (TSE:4151) Capex-to-Operating-Income : 0.29 (As of Sep. 2023)


View and export this data going back to 1949. Start your Free Trial

What is Kyowa Kirin Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Kyowa Kirin Co's Capital Expenditure for the three months ended in Sep. 2023 was 円-6,625.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was 円22,511.00 Mil.

Hence, Kyowa Kirin Co's Capex-to-Operating-Income for the three months ended in Sep. 2023 was 0.29.


Kyowa Kirin Co Capex-to-Operating-Income Historical Data

The historical data trend for Kyowa Kirin Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyowa Kirin Co Capex-to-Operating-Income Chart

Kyowa Kirin Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.38 0.60 0.32 0.35

Kyowa Kirin Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.58 0.56 0.34 0.29

Competitive Comparison of Kyowa Kirin Co's Capex-to-Operating-Income

For the Drug Manufacturers - General subindustry, Kyowa Kirin Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyowa Kirin Co's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Kyowa Kirin Co's Capex-to-Operating-Income falls into.



Kyowa Kirin Co Capex-to-Operating-Income Calculation

Kyowa Kirin Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-28666) / 82374
=0.35

Kyowa Kirin Co's Capex-to-Operating-Income for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-6625) / 22511
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co  (TSE:4151) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Kyowa Kirin Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Kyowa Kirin Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyowa Kirin Co (TSE:4151) Business Description

Traded in Other Exchanges
Address
1-9-2,Otemachi, Chiyoda-ku, Otemachi Financial City Grand Cube, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.

Kyowa Kirin Co (TSE:4151) Headlines

No Headlines